OUTLOOK THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 8.46 million shares for the 9-month period ending 2021-06-30, per its 10-Q filed 2021-08-13.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2021-08-13
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 100.00K shares, a 33.33% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 146.11K shares, a 69.73% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-12-31 was 8.22M shares, a 1372.10% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 1.53M shares, a 90.73% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 2.64M shares, a 82.24% increase from fiscal 2019.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 1.45M shares, a 595.68% increase from fiscal 2018.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 208.36K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2021-06-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | 246.11K shares derived: sum of 2 quarters · filed 2021-08-13 | 8.46M shares 10-Q · filed 2021-08-13 | 9.99M shares derived: sum of 4 quarters · filed 2021-08-13 | |
| 2021-03-31 | 146.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-14 | 8.36M shares 10-Q · filed 2021-05-14 | 9.89M shares derived: sum of 3 quarters · filed 2021-05-14 | 9.96M shares derived: sum of 4 quarters · filed 2021-05-14 | |
| 2020-12-31 | 8.22M shares 10-Q · filed 2021-02-16 | 9.74M shares derived: sum of 2 quarters · filed 2021-02-16 | 9.82M shares derived: sum of 3 quarters · filed 2021-02-16 | 10.30M shares derived: sum of 4 quarters · filed 2021-02-16 | |
| 2020-09-30 | 1.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | 1.60M shares derived: sum of 2 quarters · filed 2020-12-23 | 2.08M shares derived: sum of 3 quarters · filed 2020-12-23 | 2.64M shares 10-K · filed 2020-12-23 | |
| 2020-06-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-14 | 557.73K shares derived: sum of 2 quarters · filed 2020-08-14 | 1.12M shares 10-Q · filed 2020-08-14 | 1.92M shares derived: sum of 4 quarters · filed 2020-12-23 | |
| 2020-03-31 | 482.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-15 | 1.04M shares 10-Q · filed 2020-05-15 | 1.84M shares derived: sum of 3 quarters · filed 2020-12-23 | 2.07M shares derived: sum of 4 quarters · filed 2020-12-23 | |
| 2019-12-31 | 558.08K shares 10-Q · filed 2020-02-14 | 1.36M shares derived: sum of 2 quarters · filed 2020-12-23 | 1.58M shares derived: sum of 3 quarters · filed 2020-12-23 | 11.59K shares derived: sum of 4 quarters · filed 2020-12-23 | |
| 2019-09-30 | 800.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | 1.02M shares derived: sum of 2 quarters · filed 2020-12-23 | -546.50K shares derived: sum of 3 quarters · filed 2020-12-23 | 1.45M shares 10-K · filed 2020-12-23 | |
| 2019-06-30 | 225.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | -1.35M shares derived: sum of 2 quarters · filed 2019-08-14 | 649.50K shares 10-Q · filed 2019-08-14 | -219.22K shares derived: sum of 4 quarters · filed 2019-12-19 | |
| 2019-03-31 | -1.57M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15 | 424.50K shares 10-Q · filed 2019-05-15 | -444.22K shares derived: sum of 3 quarters · filed 2019-12-19 | 427.86K shares derived: sum of 4 quarters · filed 2019-12-19 | |
| 2018-12-31 | 2.00M shares 10-Q · filed 2019-02-14 | 1.13M shares derived: sum of 2 quarters · filed 2019-12-19 | 2.00M shares derived: sum of 3 quarters · filed 2019-12-19 | 2.04M shares derived: sum of 4 quarters · filed 2019-12-19 | |
| 2018-09-30 | -868.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | 3.36K shares derived: sum of 2 quarters · filed 2019-12-19 | 48.36K shares derived: sum of 3 quarters · filed 2019-12-19 | 208.36K shares 10-K · filed 2019-12-19 | 1.67M shares 10-K · filed 2018-12-18 |
| 2018-06-30 | 872.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | 917.08K shares derived: sum of 2 quarters · filed 2018-08-14 | 1.08M shares 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | 45.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | 205.00K shares 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | 160.00K shares 10-Q · filed 2018-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |